本文へ移動
サインイン

企業

Tenax Therapeutics, Inc.

構造マップを開く

Tenax Therapeutics, Inc. の構造

Tenax Therapeutics, Inc.

企業

関連 4 件
制約規制とエクスポージャー
自社製品と技術
関係の開始2026
Tenax Therapeutics, Inc.企業 · 関連 4 件
第 1 層

自社製品と技術2

制約規制とエクスポージャー2

関係ネットワークでの位置

118934 件中 10404 位上位 9%今週 6943 位上昇

直接の関係 3 件

密接につながる 990 件のグループに属し、中心は

今週新たに加わった関係

根拠のある公開の関係から毎日計算しています。

関係

矢印は関係の方向を示します。分野で絞り込めます。

  • Tenax Therapeutics, Inc.を使用 →levosimendan
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-06 10:21
      Tenax's prioritized product candidate is levosimendan, which the Company evaluated through, *inter alia*, its Phase 3 LEVEL study of oral levosimendan, or TNX-103, in pulmonary hypertension in heart failure with preserved ejection fraction ("PH-HRpEF").
      出典を見る
    • 企業開示PR Newswire news releases2026-11-06 10:21
      Tenax conducted and completed its Phase 2 HELP study of levosimendan
      出典を見る
    • 企業開示PR Newswire news releases2026-10-30 21:06
      Its prioritized product candidate is levosimendan, which it evaluated in the Phase 3 LEVEL study as TNX-103.
      出典を見る
    • 企業開示PR Newswire news releases2026-10-30 21:06
      which it evaluated in the Phase 3 LEVEL study as TNX-103.
      出典を見る
    • 企業開示PR Newswire news releases2026-10-28 10:25
      Tenax's prioritized product candidate is levosimendan
      出典を見る
  • Tenax Therapeutics, Inc.を使用 →TNX-103
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-10-28 10:25
      its Phase 3 LEVEL study of oral levosimendan, or TNX-103
      出典を見る
  • Tenax Therapeutics, Inc.を製造 →TNX-103
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-09 22:25
      Tenax Therapeutics is a development-stage pharmaceutical company that develops novel cardiopulmonary therapies in the United States.
      出典を見る
    • 企業開示PR Newswire news releases2026-11-09 16:32
      Tenax revealed that its Phase 3 LEVEL trial of TNX-103 failed to meet its primary and secondary endpoints.
      出典を見る
  • Tenax Therapeutics, Inc.に所在 →San Diego
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-09 22:25
      SAN DIEGO, Nov. 9, 2026 /PRNewswire/ --
      出典を見る
  • Tenax Therapeutics, Inc.の規制対象 →Securities Exchange Act of 1934
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-09 22:25
      the *Tenax Therapeutics* class action lawsuit charges Tenax Therapeutics as well as certain of Tenax Therapeutics' top current and former executives with violations of the Securities Exchange Act of 1934.
      出典を見る
  • Tenax Therapeutics, Inc.に供給 →TNX-103
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-09 22:25
      Tenax Therapeutics announced that the U.S. Food and Drug Administration had cleared Tenax Therapeutics' Investigational New Drug Application for TNX-103 (levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction, and that accordi…
      出典を見る
  • Tenax Therapeutics, Inc.を生み出す →Cardiopulmonary therapies
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-16 22:49
      develops novel cardiopulmonary therapies
      出典を見る
  • Tenax Therapeutics, Inc.の一部 →pharmaceutical industry
    事実90%
    証拠を見る
    • 企業開示PR Newswire news releases2026-11-16 22:49
      is a development-stage pharmaceutical company
      出典を見る

9 件中 1 から 8 件を表示

主張

出典とともに結論を確認し、項目を開いて証拠を読めます。

事実根拠 2

Tenax is a development-stage pharmaceutical company focused on novel cardiopulmonary therapies.

PR Newswire news releases · 2026-11-17 09:16

証拠を見る
  • 企業開示PR Newswire news releases2026-11-17 09:16
    Tenax is a development-stage pharmaceutical company focused on novel cardiopulmonary therapies.
    出典を見る
  • 企業開示PR Newswire news releases2026-11-06 10:21
    Tenax is a Phase 3, development-stage pharmaceutical company that develops novel cardiopulmonary therapies.
    出典を見る
事実根拠 2
tickerTENX

Tenax Therapeutics, Inc. (NASDAQ: TENX) securities

PR Newswire news releases · 2026-11-17 09:16

証拠を見る
  • 企業開示PR Newswire news releases2026-11-17 09:16
    Tenax Therapeutics, Inc. (NASDAQ: TENX) securities
    出典を見る
  • 企業開示PR Newswire news releases2026-11-02 03:30
    Tenax Therapeutics, Inc. (NASDAQ: TENX)
    出典を見る
事実根拠 1

is a development-stage pharmaceutical company

PR Newswire news releases · 2026-11-16 22:49

証拠を見る
  • 企業開示PR Newswire news releases2026-11-16 22:49
    is a development-stage pharmaceutical company
    出典を見る
事実根拠 1

develops novel cardiopulmonary therapies

PR Newswire news releases · 2026-11-16 22:49

証拠を見る
  • 企業開示PR Newswire news releases2026-11-16 22:49
    develops novel cardiopulmonary therapies
    出典を見る
事実根拠 1
closing price1.38 $ per share

to close at approximately $1.38 per share on August 10, 2026.

PR Newswire news releases · 2026-11-16 22:49

証拠を見る
  • 企業開示PR Newswire news releases2026-11-16 22:49
    to close at approximately $1.38 per share on August 10, 2026.
    出典を見る
事実根拠 1
に供給TNX-103

Tenax Therapeutics announced that the U.S. Food and Drug Administration had cleared Tenax Therapeutics' Investigational New Drug Application for TNX-103 (levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction, and that accordi…

PR Newswire news releases · 2026-11-09 22:25

証拠を見る
  • 企業開示PR Newswire news releases2026-11-09 22:25
    Tenax Therapeutics announced that the U.S. Food and Drug Administration had cleared Tenax Therapeutics' Investigational New Drug Application for TNX-103 (levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction, and that accordi…
    出典を見る

26 件中 1 から 6 件を表示

市場とバリュエーション

バリュエーションは Pro と Research で利用できます。

Pro で解放

監視するページを提案する

この企業について、料金、更新履歴、規約、採用など、見ておくべきページはありますか? ぜひ提案してください。提案はすべて人が確認します。追加したページはみなさん共通で監視し、続けて2回の取得が一致したときだけ変化として数えます。

サインインしてページを提案

利用できません: 企業シグナル · 財務 · 開示資料 · 拠点 · ガイダンス